Serina Therapeutics Inc (SER)
NYSEAMERICAN: SER · IEX Real-Time Price · USD
9.19
-0.81 (-8.09%)
At close: Apr 25, 2024, 4:00 PM
7.61
-1.58 (-17.20%)
After-hours: Apr 26, 2024, 4:24 PM EDT
Company Description
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain.
The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome.
Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology.
Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama.
Serina Therapeutics Inc
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Steven A. Ledger |
Contact Details
Address: 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 United States | |
| Phone | (256) 327-9630 |
Stock Details
| Ticker Symbol | SER |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| CIK Code | 0001708599 |
| ISIN Number | US81751A1088 |
| Employer ID | 82-1436829 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. J. Milton Harris Ph.D. | Co-Founder and Chairman of The Board |
| Steven A. Ledger | Interim Chief Executive Officer |
| Dr. Randall W. Moreadith M.D., Ph.D. | President and Director |
| Dr. Michael D. Bentley Ph.D. | Co-Founder, Chief Scientific Officer and Director |
| Dr. Tacey Viegas | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Apr 3, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 26, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 425 | Filing |
| Mar 7, 2024 | 8-K | Current Report |
| Mar 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |